Edition:
India

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

0.11USD
20 Sep 2019
Change (% chg)

-- (--)
Prev Close
$0.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
417,190
52-wk High
$1.29
52-wk Low
$0.09

Latest Key Developments (Source: Significant Developments)

Cancer Genetics Reports Q4 Loss Per Share $0.14
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q4 LOSS PER SHARE $0.14.QTRLY REVENUE INCREASED SEQUENTIALLY BY 15%, FROM $5.9 MILLION IN Q3 TO $6.8 MILLION IN Q4.CONTINUES TO ENGAGE RAYMOND JAMES & ASSOCIATES, INC. AS A FINANCIAL ADVISOR TO ASSIST WITH EVALUATING OPTIONS.OPTIONS MAY INCLUDE RAISING ADDITIONAL CAPITAL, ACQUISITION OF ANOTHER COMPANY AND / OR COMPLEMENTARY ASSETS.OPTIONS MAY ALSO INCLUD SALE OF COMPANY, OR ANOTHER TYPE OF STRATEGIC PARTNERSHIP.  Full Article

Cancer Genetics Announces Pricing Of $3.5 Million Public Offering Of Common Stock
Tuesday, 29 Jan 2019 

Jan 28 (Reuters) - :CANCER GENETICS, INC. ANNOUNCES PRICING OF $3.5 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 15.2 MILLION COMMON SHARES PRICED AT $0.23 PER SHARE.  Full Article

Cancer Genetics Inc Files For Non-Timely 10-Q
Thursday, 15 Nov 2018 

Nov 14 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS INC FILES FOR NON-TIMELY 10-Q.  Full Article

Cancer Genetics Appoints Glenn Miles As Chief Financial Officer
Thursday, 15 Nov 2018 

Nov 14 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS APPOINTS GLENN MILES AS CHIEF FINANCIAL OFFICER.CANCER GENETICS INC - IGOR GITELMAN, CHIEF ACCOUNTING OFFICER OF COMPANY WILL BE DEPARTING CANCER GENETICS.CANCER GENETICS INC - IGOR GITELMAN, CHIEF ACCOUNTING OFFICER OF COMPANY WILL BE DEPARTING CANCER GENETICS TO PURSUE OTHER OPPORTUNITIES.CANCER GENETICS INC - APPOINTMENT OF GLENN MILES IS EFFECTIVE NOVEMBER 26, 2018.  Full Article

Cancer Genetics And NovellusDx Sign Definitive Agreement To Merge
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS AND NOVELLUSDX SIGN DEFINITIVE AGREEMENT TO MERGE.CANCER GENETICS INC - CANCER GENETICS WILL BE SURVIVING ENTITY AND EXPECTS TO REMAIN LISTED ON NASDAQ STOCK MARKET.CANCER GENETICS INC - SHAREHOLDERS OF NOVELLUSDX WILL RECEIVE STOCK EQUAL TO APPROXIMATELY 49% OF EQUITY OF CANCER GENETICS ON A FULLY DILUTED BASIS.CANCER GENETICS - ROBERTS WILL BECOME CEO OF COMBINED COMPANY.CANCER GENETICS INC - NOVELLUSDX WILL ALSO BE PROVIDING UP TO A $2.3 MILLION BRIDGE LOAN TO CANCER GENETICS.CANCER GENETICS INC - BOARDS OF BOTH COS HAVE APPROVED PROPOSED MERGER, WHICH IS EXPECTED TO CLOSE IN Q1 2019.CANCER GENETICS INC - SIGNING OF A DEFINITIVE AGREEMENT UNDER WHICH NOVELLUSDX WILL MERGE WITH A NEWLY FORMED ISRAELI SUBSIDIARY OF CANCER GENETICS.CANCER GENETICS INC - EXISTING NOVELLUSDX SHAREHOLDERS HAVE INDICATED THAT THEY WILL INVEST $10 MILLION IN ADDITIONAL EQUITY.CANCER GENETICS INC - CHARLES WOLER, CHAIRMAN OF BOARD OF NOVELLUSDX, WILL SERVE AS CHAIRMAN OF BOARD OF COMBINED CO.  Full Article

Cancer Genetics Reports Q1 Loss Per Share $0.16
Tuesday, 15 May 2018 

May 15 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q1 LOSS PER SHARE $0.16.Q1 REVENUE ROSE 10 PERCENT TO $7.7 MILLION.  Full Article

Cancer Genetics Reports Q4 Loss Per Share Of $0.35
Tuesday, 3 Apr 2018 

April 2 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q4 LOSS PER SHARE $0.35.Q4 REVENUE $7.5 MILLION VERSUS I/B/E/S VIEW $9.2 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.11 -- THOMSON REUTERS I/B/E/S.HAS UNDERTAKEN A "COMPREHENSIVE AND EXTENSIVE" REVIEW OF ITS STRATEGY AND ORGANIZATION.ENGAGED RAYMOND JAMES & ASSOCIATES INC AS A FINANCIAL ADVISOR TO ASSIST WITH EVALUATING OPTIONS FOR COMPANY'S STRATEGIC DIRECTION.OPTIONS FOR CO'S STRATEGIC DIRECTION MAY INCLUDE RAISING ADDITIONAL CAPITAL, ACQUISITION OF ANOTHER COMPANY OR SALE OF THE COMPANY.  Full Article

Cancer Genetics Receives Non-Dilutive Funding Of $1.1 Mln
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM.CANCER GENETICS INC - ‍RECEIVED $1.1 MILLION IN NET CASH PROCEEDS FROM TRANSFER OF TAX CREDITS.  Full Article

Stonepine Capital Management Reports 5 Percent Passive Stake In Cancer Genetics
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Stonepine Capital Management::STONEPINE CAPITAL MANAGEMENT REPORTS 5 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS ON DEC 12 - SEC FILING.  Full Article

Cancer Genetics Receives New York State Approval For Oncomine Dx Target Test
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NEW YORK STATE APPROVAL FOR FDA-APPROVED ONCOMINE DX TARGET TEST BY THERMO FISHER SCIENTIFIC.  Full Article